[Primary hypothyroidism: Considerations for a rational use of levothyroxine therapy].
Bros
Jaume Arroyo
JA
Servicio de Endocrinología y Nutrición, Hospital de Sabadell, España.
Lluís
Pilar Gil
PG
Cabot
Gemma Llauradó
GL
Pedragós
Assumpta Caixàs
AC
D000328:Adult; D001281:Atrial Fibrillation / Q000139:chemically induced; D001327:Autoimmune Diseases / Q000453:epidemiology; D015897:Comorbidity; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004967:Estrogens / Q000493:pharmacokinetics / Q000502:physiology; D005260:Female; D018565:Food-Drug Interactions; D005756:Gastritis / Q000453:epidemiology; D006331:Heart Diseases / Q000453:epidemiology; D020249:Hormone Replacement Therapy; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000188:drug therapy*; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced; D011247:Pregnancy; D011248:Pregnancy Complications / Q000453:epidemiology; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*
D004967:Estrogens; D013972:Thyrotropin; D013974:Thyroxine